These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18076211)

  • 21. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Added organ protection at little cost. Double savings with ACE inhibitors].
    MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725008
    [No Abstract]   [Full Text] [Related]  

  • 23. Ramipril.
    Smith WH; Ball SG
    Int J Clin Pract; 2000 May; 54(4):255-60. PubMed ID: 10912316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.
    Ruggenenti P; Pagano E; Tammuzzo L; Benini R; Garattini L; Remuzzi G
    Kidney Int; 2001 Jan; 59(1):286-94. PubMed ID: 11135082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How cost-effective are new preventive strategies for cardiovascular disease?
    Probstfield JL
    Am J Cardiol; 2003 May; 91(10A):22G-27G. PubMed ID: 12781905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HOPE study impact on ACE inhibitors use.
    Hemels ME; Bennett HA; Bonari L; Han D; Traverso ML; Einarson TR
    Ann Pharmacother; 2003 May; 37(5):640-5. PubMed ID: 12708937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ramipril: clinical and economic benefits.
    Laking G; Lord J
    Intern Med J; 2004 Jul; 34(7):442. PubMed ID: 15271184
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
    Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
    Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
    JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More than just hype.
    Yusuf S; Dagenais G
    CMAJ; 2003 Jun; 168(13):1646; author reply 1647-8. PubMed ID: 12821614
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
    Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ramipril in the treatment of vascular diseases.
    Rokoss MJ; Teo KK
    Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
    Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.